L3VLUP
ProSign in

RVTY · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

RVTYVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • RVTY
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterRVTYVRTX
Q3 202016 holders, $3.7bn31 holders, $21.9bn
Q4 202011 holders, $3.7bn30 holders, $18.4bn
Q1 20218 holders, $3.3bn31 holders, $15.4bn
Q2 202110 holders, $4.3bn30 holders, $12.7bn
Q3 202112 holders, $5.0bn35 holders, $10.1bn
Q4 20219 holders, $6.4bn28 holders, $12.4bn
Q1 20229 holders, $6.7bn23 holders, $16.1bn
Q2 202210 holders, $5.4bn25 holders, $18.1bn
Q3 20229 holders, $2.9bn22 holders, $18.4bn
Q4 202214 holders, $3.4bn28 holders, $18.4bn
Q1 202312 holders, $3.0bn26 holders, $21.4bn
Q2 202314 holders, $2.0bn27 holders, $24.7bn
Q3 202313 holders, $2.1bn33 holders, $24.3bn
Q4 20237 holders, $1.7bn32 holders, $28.6bn
Q1 202410 holders, $1.4bn31 holders, $29.8bn
Q2 20248 holders, $1.7bn29 holders, $33.4bn
Q3 20247 holders, $2.4bn27 holders, $33.5bn
Q4 20247 holders, $2.1bn26 holders, $28.5bn
Q1 20256 holders, $2.1bn21 holders, $35.4bn
Q2 20256 holders, $1.9bn21 holders, $32.3bn
Q3 20255 holders, $1.5bn22 holders, $25.9bn
Q4 202512 holders, $2.0bn26 holders, $31.8bn
Q1 20266 holders, $1.9bn25 holders, $31.8bn
Q2 20266 holders, $1.8bn26 holders, $34.6bn
RVTY

Perkinelmer Inc

Holders
10
Reported value
$1.4bn
Buyers
7
Sellers
2

Breadth +5 among 93 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUP
VRTX

Vertex Pharmaceuticals Inc

Holders
31
Reported value
$29.8bn
Buyers
16
Sellers
19

Breadth -3 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2024

Among the 34 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only RVTY (3)

First Eagle Investment Management LLC, Holocene Advisors LP, Woodline Partners LP

Only VRTX (24)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, ARK Investment Management LLC, Artisan Partners LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital World Investors, Caxton Associates LLP, Fidelity (FMR LLC), Invesco Ltd, Man Group PLC, Neuberger Berman Group LLC, PDT Partners LLC, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, T. Rowe Price Associates Inc, Tudor Investment Corp, Two Sigma Advisers LP, Two Sigma Investments LP, Verition Fund Management LLC, Voloridge Investment Management LLC, Wellington Management Group LLP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →